Clinical Trial Update: Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies [Phase 1]

View source ↗

Summary

This is a completed Phase 1 study evaluating TPI-287 administered every 21 days in patients with advanced malignancies, including Hodgkin lymphoma and Non-Hodgk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• TPI-287

Snippet

Sponsor: Cortice Biosciences, Inc. | Conditions: Neoplasms, Hodgkin's Disease | Phase 1 | Status: COMPLETED